Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daptomycin intravenous - Merck & Co.

Drug Profile

Daptomycin intravenous - Merck & Co.

Alternative Names: Cubicin; Deptomycin; LY-146032; MK-3009

Latest Information Update: 06 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer AstraZeneca; Banyu; Cubist Pharmaceuticals; Merck & Co; Novartis; Sunovion Pharmaceuticals Canada
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacteraemia; Bacterial endocarditis; Gram-positive infections; Skin and soft tissue infections; Staphylococcal infections
  • Phase III Osteomyelitis
  • Discontinued Community-acquired pneumonia; Urinary tract infections

Most Recent Events

  • 26 Oct 2018 Phase-II clinical trials in Bacteraemia and Skin and soft tissue infections (In adolescents, In children, In infants) in Japan (IV) (NCT03720678)
  • 29 Aug 2018 Merck plans a phase II trial for Bacteraemia or Skin and soft tissue infections (In infants, In children, In adolescents) (IV) (NCT03643952)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top